Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

Cancer Science

Volumn 105, Issue 3, 2014, Pages 347-353

  Ando, Yuichi ^a   Inada Inoue, Megumi ^a   Mitsuma, Ayako ^a   Yoshino, Takayuki ^b   Ohtsu, Atsushi ^b   Suenaga, Naoko ^c   Sato, Masahiko ^c   Kakizume, Tomoyuki ^c   Robson, Matthew ^c   Quadt, Cornelia ^d   Doi, Toshihiko ^b  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NOVARTIS PHARMA K K   (Japan)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

BKM120; Buparlisib; Japanese patients

Indexed keywords

AMINOTRANSFERASE; BUPARLISIB; INSULIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; DECREASED APPETITE; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; JAPANESE; LIVER FUNCTION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOOD DISORDER; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; RASH; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

BKM120; BUPARLISIB; JAPANESE PATIENTS;

ADULT; AGED; AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; JAPAN; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895517907     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12350     Document Type: Article

References (50)

1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-19.
2. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-44.
3. Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564-9.
4. Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009; 108: 180-94.
5. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and anti-estrogen resistance in breast cancer. J Clin Oncol 2011; 29: 4452-61.
6. Maira SM, Pecchi S, Huang A et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-Kinase inhibitor. Mol Cancer Ther 2012; 11: 317-28.
7. Ren H, Chen M, Yue P et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 2012; 325: 139-46.
8. Mueller A, Bachmann E, Linnig M et al. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 2012; 69: 1601-15.
9. Park E, Park J, Han SW et al. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol 2012; 40: 1259-66.
10. Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282-90.
11. Grana B, Burris H, Rodon J et al. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy. J Clin Oncol 2011; 29 (suppl; abstr 3043).
12. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008; 27: 2420-39.
13. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: Efficient dose escalation with overdose control. Stat Med 1998; 17: 1103-20.
14. Von Hoff DD, LoRusso P, Tibes R et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2010; 28 (suppl; abstr 2541).
15. Munster PN, van der Noll R, Voest EE et al. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). J Clin Oncol 2011; 29 (suppl; abstr 3018).
16. Hong DS, Bowles DW, Falchook GS et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 4173-82.
17. Japanese Health Authority, 2008. Manual for drug-induced liver injury by the Ministry of Health, Labour and Welfare (in Japanese). Available from URL: http://www.info.pmda.go.jp/juutoku/juutoku_index.html
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2009. Guidance for Industry. Drug-induced liver injury: premarketing clinical evaluation. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf.
19. Shimizu T, Tolcher AW, Papadopoulos KP et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012; 18: 2316-25.
20. Markman B, Tabernero J, Krop I et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23: 2399-408.
21. Crouthamel MC, Kahana JA, Korenchuk S et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009; 15: 217-25.
22. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96.
23. Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3K family defines a role for p110alpha in insulin signaling. Cell 2006; 125: 733-47.
24. Ready NE, Dudek AZ, Pang HH et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011; 29: 4436-41.
25. Pontes LB, Armentano DP, Soares A, Gansl RC. Fatal pneumonitis induced by oxaliplatin: description of three cases. Case Rep Oncol 2012; 5: 104-9.
26. Fuse N, Doi, Ohtsu A, T, Ohtsu A et al. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. Jpn J Clin Oncol 2007; 37: 434-9.
27. Nakagawa M, Hamada A, Yoshihara Y et al. A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Gan To Kagaku Ryoho 2011; 38: 317-20.
28. Hardy R, Cummings C, Faulkner M, Obianyo I. Pneumocystis carinii pneumonia following 5-fluorouracil administration. J Natl Med Assoc 1987; 79: 1205-9.
29. Fukuda M, Soda H, Fukuda M et al. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced non-small-cell lung cancer: a multi-institutional phase 2 study. Cancer 2007; 110: 606-13.
30. Takeda K, Negoro S, Kudoh S et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 1999; 79: 1462-7.
31. Chakravarthy AB, Tsai CJ, O'Brien N et al. A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Gastrointest Cancer Res 2012; 5: 112-18.
32. Blumenschein GR Jr, Paulus R, Curran WJ et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011; 29: 2312-18.
33. Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-80.
34. Maroto JP, Hudes G, Dutcher JP et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29: 1750-6.
35. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65.
36. White DA, Camus P, Endo M et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403.
37. Soria JC, Shepherd FA, Douillard JY et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20: 1674-81.
38. Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012; 51: 873-9.
39. Nanni P, Nicoletti G, Palladini A et al. Multiorgan metastasis of human HER-2(+) breast cancer in Rag2(-/-);Il2rg(-/-) mice and treatment with PI3K inhibitor. PLoS ONE 2012; 7: e39626.
40. Maira M, Schnell C, Lollini P et al. Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3K inhibitor, in the brain. Ann Oncol 2012; 23 (suppl; abstr 1675).
41. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-73.
42. Beaulieu JM, Sotnikova TD, Yao WD et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099-104.
43. Chen L, Han L, Shi Z et al. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol Med Rep 2012; 5: 575-9.
44. Bychkov E, Ahmed MR, Dalby KN, Gurevich EV. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 2007; 102: 699-711.
45. Janku F, Tsimberidou AM, Garrido-Laguna I et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10: 558-65.
46. Janku F, Wheler JJ, Westin SN et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-82.
47. Juric D, Baselga J. Tumor genetic testing for patient selection in phase I clinical trials: The case of PI3K inhibitors. J Clin Oncol 2012; 30: 765-6.
48. Ihle NT, Lemos R Jr, Wipf P et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009; 69: 143-50.
49. O'Brien C, Wallin JJ, Sampath D et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010; 16: 3670-83.
50. Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2012; 39: 313-20.